Tolerogenic nanoparticles restore the antitumor activity of recombinant immunotoxins by mitigating immunogenicity [Medical Sciences]

Protein-based drugs are very active in treating cancer, but their efficacy can be limited by the formation of neutralizing antidrug antibodies (ADAs). Recombinant immunotoxins are proteins that are very effective in patients with leukemia, where immunity is suppressed, but induce ADAs, which compromise their activity, in patients with intact immunity....

http://ift.tt/2BoR0Ly